News
CMRX
1.060
+4.95%
0.050
Weekly Report: what happened at CMRX last week (0318-0322)?
Weekly Report · 4d ago
Chimerix Board Changes: Machado Resigns, Kozin Appointed
Patrick Machado has announced his resignation from the Board of Directors of Chimerix. Marc Kozin has been appointed as a Class III director of the company. Machado cited no disagreements with the company’s operations or policies. CMRX stock is down 10% in the past week.
TipRanks · 03/21 12:42
Press Release: Chimerix Appoints Marc D. Kozin to Board of Directors
Chimerix Appoints Marc D. Kozin to Board of Directors Veteran Industry Executive Brings More Than 35 years of Corporate Strategy Experience. Patrick Machado has announced his retirement from the Chimerix Board effective at the 2024 Annual Meeting of Stockholders in June.
Dow Jones · 03/21 11:00
Weekly Report: what happened at CMRX last week (0311-0315)?
Weekly Report · 03/18 10:37
Weekly Report: what happened at CMRX last week (0304-0308)?
Weekly Report · 03/11 10:35
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
TipRanks · 03/05 06:31
Weekly Report: what happened at CMRX last week (0226-0301)?
Weekly Report · 03/04 10:37
Chimerix: Tackling A Strong Unmet Need With Promising Data
Seeking Alpha · 03/01 20:31
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 03/01 12:22
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Benzinga · 03/01 12:14
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Bio-Rad Laboratories (BIO)
TipRanks · 03/01 11:30
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Chimerix (CMRX)
TipRanks · 03/01 03:00
Analysts’ Top Healthcare Picks: Chimerix (CMRX), MoonLake Immunotherapeutics (MLTX)
TipRanks · 02/29 20:10
Buy Rating Affirmed for Chimerix Amid Progress in Dordaviprone’s Phase III Study and Strong Financial Outlook
TipRanks · 02/29 16:55
Chimerix Inc reports results for the quarter ended in December - Earnings Summary
Chimerix Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 20 cents per share. Revenue fell 99.5% to $4.00 million from a year ago. Chimerix shares had risen by 28.8% this quarter.
Reuters · 02/29 14:33
Chimerix Unveils New Corporate Presentation for Investors
TipRanks · 02/29 13:14
*Chimerix 4Q Research and Development Expenses $15.6M >CMRX
Dow Jones · 02/29 12:08
Chimerix GAAP EPS of -$0.20 beats by $0.03
Seeking Alpha · 02/29 12:05
*Chimerix 4Q Loss $18.2M >CMRX
Dow Jones · 02/29 12:00
*Chimerix 4Q Loss/Shr 20c >CMRX
Dow Jones · 02/29 12:00
More
Webull provides a variety of real-time CMRX stock news. You can receive the latest news about Chimerix through multiple platforms. This information may help you make smarter investment decisions.
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.